Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
Public ClinicalTrials.gov record NCT03284424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Study identification
- NCT ID
- NCT03284424
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2017
- Primary completion
- Jul 28, 2020
- Completion
- Sep 12, 2023
- Last update posted
- Aug 22, 2024
2017 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores UC San Diego Cancer Center ( Site 0352) | La Jolla | California | 92093-0880 | — |
| Stanford University Medical Center ( Site 0366) | Palo Alto | California | 94305 | — |
| St. Joseph Heritage Healthcare ( Site 0350) | Santa Rosa | California | 95403 | — |
| Yale University ( Site 0365) | New Haven | Connecticut | 06520 | — |
| Lombardi Comprehensive Cancer Center ( Site 0360) | Washington D.C. | District of Columbia | 20007 | — |
| Indiana University Melvin and Bren Simon Cancer Center ( Site 0353) | Indianapolis | Indiana | 46202 | — |
| University of Kansas Cancer Center ( Site 0361) | Westwood | Kansas | 66205 | — |
| Massachusetts General Hospital ( Site 0362) | Boston | Massachusetts | 02114 | — |
| Comprehensive Cancer Centers of Nevada ( Site 8001) | Las Vegas | Nevada | 89148 | — |
| John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0367) | Hackensack | New Jersey | 07601 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0364) | Tulsa | Oklahoma | 74146 | — |
| Fox Chase Cancer Center ( Site 0351) | Philadelphia | Pennsylvania | 19111 | — |
| Sanford Cancer Center Oncology Clinic ( Site 0356) | Sioux Falls | South Dakota | 57104 | — |
| Texas Oncology PA ( Site 8000) | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03284424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03284424 live on ClinicalTrials.gov.